Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
Status:
Completed
Trial end date:
2019-07-07
Target enrollment:
Participant gender:
Summary
Cannabis Hyperemesis Syndrome (CHS) has become a well-documented syndrome since 2004 and is
expected to increase in prevalence with continuing liberalization of marijuana and
recognition of the disease. Regardless of whether the association with heavy cannabis use is
recognized, there is well-documented resistance to traditional anti-emetic treatment. Given
promising reports of the use of intravenous haloperidol, a randomized controlled trial
comparing it to the commonly administered anti-emetic ondansetron will contribute to the
management of CHS